跳至主要内容

A.C.E.| Seminar 3：Exploring the Intersection of Al,Gene Editing, and RNA Therapeutics



Date: Sunday, May 14-1-4pm PDT160 E Tasman Dr

Address: 160 East Tasman Drive San Jose, CA 95134 United States
Organizer: CBA (Chinese Bioscience Association)
Co-organizers: Medicilon, Q BAY center Media partner: CABS (Chinese-American Bio/Pharmaceutical Society)

Gene- and RNA-based therapies show significant promise.  Gene editing aims to treat genetic disease through altering gene expression.  Programmable editing of nucleic acids offers significant therapeutic potential for a wide range of genetic diseases. Gene- and RNA-based therapies need substantial innovation to unlock full potential for patients.  Scaling digital and analytics in discovery and R&D is part of the solution.  Applying artificial intelligence (Al) to R&D for novel therapeutic modalities brings new opportunity. Let's explore the intersection of Al, gene editing, and RNA therapeutics!

Dr. Ho Leung Ng

the founder of Rise Bio

Dr. Ng is the founder of Rise Bio, a startup working on Al drug discovery for drug-resistant breast and prostate cancer.  Dr. Ng was a Principal Scientist at Atomwise, a leading Al drug discovery company.  Dr. Ng spent most of his career in academia, as a professor of biochemistry at Kansas State University and professor of chemistry at the University of Hawaii.  Dr. Ng completed his PhD at UCLA and postdoc at UC Berkeley.  He then worked as a Senior Scientist at ConfometRx under founder, future Nobel Laureate Brian Kobilka, on G-protein coupled receptor crystallography.  Dr. Ng was the recipient of the US National Science Foundation CAREER Award for early career scientists.  Dr. Ng's current research focuses on generative models for drug discovery, quantum chemistry, closed loop automation for hit-to-lead and lead optimization, and identifying drug binding sites in proteins.

Chenjian Li, Ph.D.

currently on the faculty of Stanford University

Dr.  Chenjian Li is currently on the faculty of Stanford University.  He has been a Chair Professor of Peking University.  He is on the China Advisory Board of Eli Lilly and Company, and the China Advisory Board of Cornell University.  Dr. Li is also a bio-tech entrepreneur who co-founded and successfully established Novita Pharmaceutical Inc., developing anti-cancer metastasis first-in-class drug which is in Phase Il trial in USA.Dr.  Li is an alumnus of Peking University Biology Department and Peking Union Medical College was the former Vice Provost of Peking University, Executive Dean of Yuanpei College, and Associate Dean of School of Life Science, Peking University.  Prior to his return to China, he was an assistant professor and associate professor at Weill Medical College of Cornell University (2003—2009), and then Aidekman Endowed Chair of Neurology at Mount Sinai School of Medicine (2010-2013).  Dr. Li's scientific achievement is in the field of molecular and cellular mechanisms of neurological diseases. Parallel to research, Dr. Li is devoted to education reforms for the next generation of global-citizen leaders, ranging from high school, undergraduate, graduate and medical student education.  He was one of the organizers of the influential "Science Outreach Program" in USA.  Since his move to China, he has played a leading role in important initiatives such as the establishment of Cambridge-PKU Center for China Study, inauguration of Rhodes Scholar program in China, reform of college admission by holistic evaluation, design and implementation of liberal education curriculum at PKU, etc.  He received many awards for excellence in teaching, including a student-voted "Pied Piper Mater" at Weill Cornell Medical College in 2006, a student-voted "Best Teacher" at PKU in 2015, Outstanding Educator Award by the world-wide Chinese Biological Investigator Society in 2016, and Outstanding Teaching Award from Peking University Life Science in 2019.  He also received 2001 National Book Award for the translation of Richard Feynman's book into Chinese.

Renzong Xie, DABT Ph.D.

currently VP of Toxicology from Medicilon

Dr. Renzong Xie is currently VP of Toxicology from Medicilon. He has been serving in the pharmaceutical industry for more than thirty years, including twelve years of working experience in CDE in Taiwan. Dr. Xie was responsible for reviewing the pharmacological and toxicological test reports of IND and NDA applications, writing review reports and conducting risk assessments. He reviewed more than 200 IND cases, including 70 biologics drugs and more than 150 NDA cases, of which about 40 biologics drugs. He has also drafted the guidelines for CDE non-clinical safety trials of Taiwan, ICH S9 and E14/S7B, and several guidelines for non-clinical safety trials of Taiwan. In addition, Dr. Xie is also experienced in pharmacology and toxicology research, establishment of disease animal models, and the whole process of new drug development. These experiences will further promote the development of Medicilon toxicology research and improve the quality, efficiency and successful rate of project submissions. Before joining Medicilon, Dr. Xie served as a senior executive in Jiangxi Changpharma Inc., LongBio Pharma, and Oneness Biotech, and has excellent experience in new drug R&D and team management.Dr. Xie received his Ph.D. in Pharmacology and Toxicology, University of Mississippi, USA, Certified Toxicologist of the DABT, former member of the Drug Development Program Review Committee of the National Science Society of Taiwan, Ministry of Science and Technology and Ministry of Economic Affairs and the Professor of Taipei Medical University and Biotech Industrial Academy.

About Medicilon

Medicilon is a professional pharmaceutical preclinical integrated R&D service contract research organization (CRO), providing a full range of one-stop new drug R&D services, in compliance with Chinese and international filing standards, to pharmaceutical companies and research institutions around the world. Our services cover the entire process of preclinical new drug research, including drug discovery, pharmacology research and preclinical research.We focus on the needs of innovation and development of global pharmaceutical industry, based on the key aspects of R&D of innovative drug, and build a comprehensive technology platform covering drug discovery, pharmacological research and preclinical research key technologies with our rich experience in serving the Chinese and international biopharmaceutical industry. For enquiries, please visit our website: www.medicilon.com or email: marketing@medicilon.com.

标签：

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...
发表评论
阅读全文